Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Manchester University

- PMLiVE

GSK buys rights to MorphoSys’ arthritis antibody

Pharma company will pay up €445m to develop and commercialise MOR103

- PMLiVE

AstraZeneca drops arthritis candidate fostamatinib

Hands rights back to Rigel after late-stage trial disappointment

- PMLiVE

EMA refuses to back Pfizer’s Xeljanz in rheumatoid arthritis

Surprise after approvals in US and Japan

- PMLiVE

From marketing to medical: Pharma’s informational source shift

The changing role of medical information in HCP communications pathways

- PMLiVE

Quality Standards – are we making the most of them?

As the UK health service enters a new chapter, NICE begins developing best practice guidelines

- PMLiVE

Communicating clearly: using PowerPoint properly

How to design and use data slides that really add to your presentation.

- PMLiVE

Virgo Health opens New York and Singapore offices

Susan Cuozzo will head the US team and Rachel Norager the Singapore team

- PMLiVE

Swedish regulator rules Boehringer press release is advertising

German pharma company fails to appeal decision

- PMLiVE

Lilly abandons tabalumab for rheumatoid arthritis

Decision based on lack of efficacy in late-stage trials

UCB launches arthritis exercise programme in the UK

Scheme was piloted at two NHS Trusts during 2011

- PMLiVE

Lilly stops tabalumab trial in arthritis on efficacy grounds

Will take a charge of around $20m to $35m

- PMLiVE

AstraZeneca’s fostamatinib fails to match Humira in RA

Inferiority to Abbott’s drug dents commercial prospects

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links